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Summary The tumour suppressor gene p53 has been found to be mutated or inactivated at high frequency in
several common human tumours. We have examined a series of exocrine pancreatic carcinomas for over-
expression of mutant forms of p53 by immunohistochemistry with a panel of specific antibodies. We found
immunodetectable p53 in 13 of 22 (60%) frozen pancreatic cancers and seven of 13 pancreatic cell lines. One
of the antibodies, CM1, recognises p53 in formalin-fixed, paraffin-embedded archival material and using this
reagent we found immunodetectable p53 in 28 of 124 (23%) pancreatic cancers. We have successfully
demonstrated the presence of point mutations by direct sequencing of genomic DNA extracted from archival
tissue showing CM1 immunoreactivity. We conclude that p53 activation is an important event in human
pancreatic tumorigenesis and that the CM1 antibody can detect a proportion of cases of overexpression of
mutant p53 in archival pathological material.
Carcinoma of the exocrine pancreas is the fourth most com-
mon cause of death from cancer, leading to 6,000 deaths per
year in the UK, and its incidence appears to be rising in
Western nations (Williamson, 1988). Conventional methods
of treatment including surgery, radiotherapy and
chemotherapy offer little hope of cure and 5-year survival is
reported as less than 1% with a median survival of 2.8
months (Cancer of the Pancreas Task Force Group 1981).
Little is currently known of its aetiology and pathogenesis,
but analysis of the involvement of oncogenes and tumour
suppressor genes might enable us to understand better the
molecular basis of this cancer and possibly to design new
therapeutic strategies (Lemoine & Hall, 1990).
Among the most striking genetic changes in human pan-
creatic cancer is the very high frequency point mutation at
codon 12 of the Ki-ras oncogene, which affects around 75%
of cases (reviewed by Shibata et al., 1990). Much interest is
now focussed on oncogenic events that might cooperate with
the Ki-ras oncogene in pancreatic tumorigenesis, and
amongst the potential candidates is point mutation of the
p53 tumour suppressor gene. Abnormalities of the p53 gene
occur at very high frequency in several common human
malignancies (see for example Nigro et al., 1989; Bartek et
al., 1990; Takahashi et al., 1989; Baker et al., 1990), and at
least some mutant forms of this gene can cooperate with
activated ras oncogenes to produce full cellular transforma-
tion in vitro (Hinds et al., 1990). We have therefore investi-
gated the prevalence of abnormalities of the p53 protein in
human pancreatic cancer using a panel of monoclonal and
polyclonal antibodies, and confirmed the presence of point
mutations in cases of abnormal protein expression using
PCR amplification and direct sequencing of cDNA and
genomic DNA.
Materials and methods
Tumour samples
Our study material comprised 22 human pancreatic cancer
samples which had been snap-frozen in liquid nitrogen after
surgical resection and subsequently stored at - 70°C, and
124 human pancreatic cancer samples in formalin-fixed,
paraffin-embedded tissue blocks taken from the pathological
archives of Hammersmith Hospital in London and the
Academic Hospital Jette in Brussels. The tumours were
classified and graded using established histopathological
criteria (Kloppel & Maillet, 1989).
We also studied 13 pancreatic cancer cell lines, some of
which we obtained from the American Type Culture Collec-
tion (MiaPaCa-2, BxPC-3, CaPan-1, CaPan-2, AsPC-1, PSN-
1) and others which we acquired from their original sources.
The 818.1 and 818.4 cell lines were gifts from Dr H. Kalthoff
and Dr W. Schmiegel, Department of Immunology, Univer-
sity Hospital Eppendorf, Hamburg, Germany.
Immunohistochemistry
Frozen sections and tissue culture cells Five micron thick
sections of primary human pancreatic cancers and tissue
culture cells grown on multiwell slides were fixed in 50%
acetone/50% methanol for 2 min and washed with
phosphate-buffered saline (PBS). Endogenous peroxidase
activity inhibited by incubation of the specimen in 0.1%
phenylhydrazine hydrochloride for 5 min at room
temperature. The section was then incubated with the
primary antibody for 1 h at room temperature (monoclonal
antibodies as neat hybridoma supernatant, and the poly-
clonal antiserum JG8 as a 1/500 dilution in 0.5% bovine
serum albumin (BSA) in PBS). The primary antibody was
detected using the avidin-biotin complex method (ABC
system from Dako Ltd) with diaminobenzidine tetrahydroch-
loride as the chromogen.
Paraffin sections Two micron sections were dewaxed in
xylene and passed through alcohol and washed in PBS.
Endogenous peroxidase activity was blocked by incubation
of the slide in 0.3% hydrogen peroxide in PBS for 30 min at
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room temperature. The section was then incubated for 1 h at
room temperature in the polyclonal antiserum CM1 diluted
1 in 800 in 0.5% BSA in PBS. The primary antibody was
detected using the ABC system with diaminobenzidine tetra-
hydrochloride as the chromogen.
Controls Positive controls comprised cell lines previously
shown to express p53 genes with activating point mutations
(Bartek et al., 1990) and negative controls consisted of
replacement of the primary antibody with buffer alone.
Antibodies
Monoclonal antibody PAbl8O1 recognises a denaturation-
resistant epitope between amino acids 32 and 79 (Banks et
al., 1986), PAb421 recognises a denaturation-resistant epitope
located between amino acids 370 and 378 of p53 (Wade-
Evans & Jenkins, 1985), and PAb240 recognises a denatur-
ation-resistant epitope located between amino acids 156 and
335 (Gannon et al., 1990).
JG8 is a high-titre rabbit antiserum raised against a large
fragment of murine p53 purified from Escherichia coli con-
taining an expression plasmid (Iggo et al., 1990), CM1 is a
high-titre rabbit antiserum raised against full-length recom-
binant human p53 (Bartek et al., 1991).
Immunoprecipitation
Cells were lysed in 150mM NaCl, 50 mM Tris pH 8, 5 mM
EDTA, 1% NP40, 1 mM PMSF for 30 min on ice. The cell
extract was centrifuged at 100,000g for 30 min and the pellet
was discarded. The extract was preadsorbed with protein G
sepharose (Pharmacia), neat hybridoma supernatant was
added and the mixture was left overnight at 4°C on a
rotating wheel. Protein G beads were added and the incuba-
tion was continued for 1 h. The beads were then washed four
times in lysis buffer. Denaturing polyacrylamide gel electro-
phoresis and immunoblotting were performed as described in
Harlow & Lane (1988) and Bartek et al. (1990). Immunoblots
were blocked in 0.1% Tween 20 in PBS, probed overnight at
4°C with rabbit anti-p53 serum JG8 (Gannon et al., 1990)
diluted 1 in 100 and washed in 0.1% Tween 20 in PBS. The
blots were then incubated for 2 h at room temperature in
sheep anti-rabbit IgG conjugated to alkaline phosphatase,
and bands were visualised after the addition of 5-bromo-4-
chloro-3-indoyl phosphate and nitro blue tetrazolium (Pro-
mega Inc.).
PCR sequencing
p53 cDNA sequencing This was carried out on amplified
cDNA from mRNA extracted from the pancreatic cell lines
using the oligonucleotide primers and protocols described by
Bartek et al. (1990).
p53 genomic DNA sequencing from cell lines and frozen
tumour tissue This was carried out using the oligonucleotide
primers and protocols described by Baker et al. (1990).
p53 genomic DNA sequencing from archival tumour tis-
sue The following oligonucleotides were used for
amplification and sequencing of genomic DNA extracted
from formalin-fixed, paraffin-embedded pathology tissue sec-
tions
9618 5' CTGGGTACCTTCCTCTTCCTGCAGTACTCCCCT 3'
9619 5' GGAATTCGCCCCAGCTGCTCACCATCGCTA 3'
12816 5' AGTGGGTTGCAGGAGGTGCT 3'
12612 5' GGGCCAGACCTAAGAGCAATCAGTG 3'
9214 5' TCCTAGGTTGGCTCTGACTGT 3'
9315 5' AGTGGCTCCTGACCTGGAGTC 3'
12613 5' TGGGCGACAGAGCGAGATTCCATCT 3'
12614 5' AGTATGGAAGAAATCGGTAAGAGGT 3'
9213 5' CCTATCCTGAGTAGTGGTAAT 3'
9212 5' TCCTGCTTGCTTACCTCGCTT 3'
12615 5' TGGGAGTAGATGGAGCCTGG 3'
12616 5' AGGAAAGAGGCAAGGAAAGG 3'
We have recently described the use of these primers
(Wright et al., 1991) which were derived from p53 genomic
sequence reported by Chumakov and colleagues (Buchman et
al., 1988; Chumakov et al., 1990), and their location and
strategy for use is shown in Figure 1. DNA for amplification
was prepared from paraffin-embedded tissue sections as
previously described (Lemoine et al., 1989; Higuchi, 1989),
and symmetric amplification was performed on DNA derived
from individual sections using 100 pmol for each primer, 2.5
units of thermostable DNA polymerase (Replinase from
Dupont (UK) Ltd), 200LM dNTPs in a total volume of
100pl buffer (50mM Tris pH 9, 20 mM ammonium sulphate,
1.5mM MgCl2). Thirty to 50 cycles of amplification were
performed in Cetus Thermal Cycler. Essentially, DNA
amplification was performed with a pair of outboard primers
around either exon 5, exon 7 or exon 8, and then the
amplified fragment purified by excision of the specific band
from a 2.5% agarose gel (2% Nusieve, 0.5% Seakem) and
recovery of the DNA by electrophoretic concentration
(Extraphor Electrophoretic Concentrator, LKB Pharmacia).
10 ng of template DNA was mixed with 20 pmol of relevant
inboard primer in a final volume of 8 1I and denatured by
heating to 98°C for 7 min, and then 2 il of 5 x Sequenase
reaction buffer (United States Biochemical) added. The mix-
ture was then incubated at 37°C for 30 min, then at room
temperature for 10 min and finally on ice before proceeding
with the standard Sequenase Version 2.0 (United States
Biochemical) sequencing protocol using 3"S-dATP.
Results
Nuclear immunoreactivity
Of the 22 primary exocrine pancreatic carcinomas studied by
immunohistochemistry in frozen sections, 13 (60%) possessed
nuclear immunoreactivity with the JG8 and CM1 polyclonal
antisera and of these 11 had immunoreactivity with the
mutant-specific monoclonal antibody 240 (PAb240). Not all
malignant cells within an individual tumour were positive,
and the percentage of cells showing definite immunoreactivity
with either antibody varied from 20% up to 90%. Cases in
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Figure 1 Regions of p53 gene exons 5, 7 and 8 analysed in genomic DNA extracted from archival pathology specimens. The
conserved regions II, III, IV and V are indicated in the exons 5 through 8, and the numbered arrowheads represent the position of
the primers used for DNA amplification and sequencing.1078 C.M. BARTON et al.
which there was faint cytoplasmic staining without nuclear
staining were not scored as positive in this analysis.
Seven of the 13 cell lines examined by immunocytochemi-
stry on cells grown on glass slides showed nuclear
immunoreactivity with PAb240, PAb421, PAbl8O1 and the
polyclonal antiserum CM1 (Table I); six of these cell lines
also showed reactivity with the antiserum JG8. There was
some variation in the preparation of cells positive with each
test (Table I).
The polyclonal antiserum CMI was used to detect p53
immunoreactivity in 124 pancreatic carcinoma cases in
routinely-processed paraffin sections. Twenty-eight cases
(23%) were positive for nuclear immunoreactivity with this
antiserum (Figure 2). The percentage of positive tumours did
not vary significantly with pathological grade (Table II). In
some cases there was definite cytoplasmic staining in addition
to convincing nuclear positivity. We did not observe this
phenomenon in frozen sections tested with this antibody, and
it may represent an effect of fixation and processing. Five
Table H Abnormalities of p53 expression in paraffin-embedded
cases of pancreatic cancer detected with CM1 antiserum
Tumour gradea 1 2 3
CM1 immunoreactive/total 11/52 12/48 5/24
% Immunoreactive 21% 25% 21%
aGrade as defined by Kloppel and Maillet (1989), with grade 1
tumours having lowest mitotic activity and best differentiation.
cases of intraductal carcinoma (which is thought to represent
an earlier stage of tumorigenesis than invasive carcinoma,
analogous to the situation in breast cancer) were examined
with the CM1 antiserum, and two of these showed nuclear
immunoreactivity in tumour cells.
Immunoprecipitation studies
Thirteen pancreatic cancer cell lines were examined in
immunoprecipitation assays with the monoclonal antibodies
Table I Abnormalities of p53 in human pancreatic carcinoma cell lines
Immuno-
Immunocytochemistrya precipitationb Sequence
240 1801 421 JG8 CMI 240 1801 analysis
Pancl ++++ ++++ ++++ +++ ++++ ++ ++++ CGT273+ CAT273
MiaPaCa2 ++++ ++++ ++++ ++++ ++++ +++ ++++ CGG24)+TGGC24
PT45 ++++ ++++ ++++ +++ ++++ ++ ++++ AGA280+AAA280
HPAF + + + + + +/- + CCC'5+ CTC15'
PSN1 + + + + + + + + + + + + AAG'32+ CAG'32
CaPanl + + + + + +++ + + + - - None detected
CaPan2 - - - - - - - None detected
CaPIM - - - - - - - None detected
AsPcl - - - - - - - None detected
BxPc3 + + + - + - - None detected
818.1 - - - - - - - None detected
818.4 - - - - - - - None detected
Colo357 - - - - - - - None detected
aPositive signals were graded for proportion of cells with nuclear staining (+ <25%, + + 25-50%, + + + 50-75%,
+ + + + 75-100%). bPositive signals were graded for intensity (+ to + + + +).
Figure 2 Immunoreactivity for p53 detected with the CM1 antiserum in a formalin-fixed, paraffin-embedded pancreatic adenocar-
cinoma grade 2 showing typical perineural invasion. The tumour cells show dense nuclear immunoreactivity while the stromal cells
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PAbl801 and 240. Five cell lines had detectable p53 (Figure 3)
on immunoprecipitation with antibody PAbl80l, and four of
these also showed a band of lesser intensity on immuno-
precipitation with the mutant-specific antibody PAb240
(Table I).
Point mutations ofp53 gene
Several studies have established that immunoreactivity with
monoclonal anti-p53 antibodies PAb421, 240 and 1801 is
associated with point mutations of the p53 gene (Iggo et al.,
1990; Rodrigues et al., 1990). All ofthe previous studies have
been restricted to frozen tumour samples or cell lines because
the monoclonal antibodies available do not recognise p53 in
formalin-fixed material, and the techniques developed to
identify point mutations have been designed for use on
cDNA or high molecular weight genomic DNA. We have
developed a sequencing strategy (Wright et al., 1991) that can
be applied to the low molecular weight genomic DNA
obtainable from fixed tissue sections, amplifying the most
conserved parts of p53 in exons 5, 7 and 8 representing the
'hot spots' for mutation (Baker et al., 1990) in box II (codon
132-145), box III (codon 171-179), box IV (codon
239-248) and box V (codon 272-286).
To examine the relationship between immunoreactivity
with the CM1 antiserum in formalin-fixed, paraffin-embedded
material and p53 point mutations, we attempted
amplification and sequence analysis in eight tumours with
positive nuclear staining and four tumours without staining.
We failed to amplify specific DNA in three of the CMl-
positive cases and in one of the CM1-negative cases. We
found point mutations in three of the CM1-positive cases
(codon 246 ATG to ATT, methionine to isoleucine; codon
249 AGG to AAG, arginine to leucine; codon 273 CGT to
CAT, arginine to histidine), confirmed on both sense and
antisense strands. We infer that the mutant gene is
hemizygous in each of these cases because the band represent-
ing wild type sequence is absent or much weaker than the
band for the mutant sequence (Figure 4). We do not have
high molecular weight DNA available for these cases and so
are unable to confirm allelic deletions by RFLP analysis of
chromosome 17p. Only wild type sequence was present in the
CM1-negative cases. In this small series point mutations in
the hot spots were therefore restricted to CM1-positive cases,
although of course we have not excluded abnormalities in
other areas of the p53 gene.
We used direct sequencing of product amplified from
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Figure 3 Immunoblot of immunoprecipitates from pancreatic cancer cell lines. Extracts were immunoprecipitated with PAb240
or
PAbl8O1 for each cell line. Immunoblots were probed with rabbit anti-p53 serum JG8 at 1/100 dilution.
genomic DNA and cDNA of each of the cell lines to confirm
expression of a mutant p53 gene. Point mutations of the
coding sequence in exons 5, 6, 7 and 8 were identified (Figures
5 and 6) in all of the cell lines overexpressing p53 by
immunoprecipitation analysis (Panc-1, HPAF, PT45,
MiaPaCa-2 and PSN-1). The CaPanl and BxPc3 cell lines
were positive by immunocytochemistry but negative by
immunoprecipitation analysis, and no mutation in any exon
was identified in these lines. Since p53-immunoreactive cells
form only a minority population in the BxPc3 cell line it is
possible that we could miss a mutation by the direct sequenc-
ing technique, particularly ifthe mutation is heterozygous. The
explanation for our failure to identify an activating mutation
in the CaPanl cell line is currently obscure, but it is interesting
that immunoprecipitation analysis failed to detect high levels
ofmutant p53 in contrast to the immunocytochemical analysis.
None of the cell lines that lacked immunoreactive p53 protein
possessed point mutations in any exon.
Discussion
Our results indicate that p53 abormalities occur at high
frequency in pancreatic cancer, similar to the frequencies
reported in other common human malignancies such as col-
orectal cancer (Rodrigues et al., 1990; Baker et al., 1990),
breast cancer (Bartek et al., 1990), lung cancer (Chiba et al.,
1990) and hepatocellular cancer (Hsu et al., 1991; Bressac et
al., 1991).
Using frozen tissue and a panel of anti-p53 antibodies
(including the CM1 polyclonal antiserum) we detected
overexpression of mutant p53 protein in 60% of cases of
pancreatic cancer. With paraffin sections, using only the
CM1 antiserum, we found a smaller proportion of cases
(20-25%) showing nuclear immunoreactivity. This difference
in p53 immunoreactivity is probably because the epitope
recognised by CM1 antiserum is only partially resistant to
formalin fixation. Examination of genomic DNA extracted
from representative paraffin sections confirmed that point
mutations were present in conserved regions of the p53 gene
in those cases showing positive p53 immunoreactivity.
Sequence analysis of those cases expressing high levels of
p53 protein also allowed identification of a point mutation in
the coding sequence of exons 5, 6 7 or 8 in most cases. The
nature of the base change involved showed no special
predilection, with G to A transitions, C to T transitions and
G to T transversions identified in this series. In non-small cell
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Figure 4 Sequencing of p53 in genomic DNA extracted from archival pathology specimens. Two cases, lanes 2 and 4, show
mutations in the coding sequence in conserved region IV.
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Figure 5 Sequencing ofp53 in genomic DNA from pancreatic cell lines. The MiaPaCa-2 cell line shows a mutation at codon 248
(CGG to TGG, amino acid arginine to tryptophan) in conserved region IV.
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Figure 6 Sequencing of p53 in genomic DNA from pancreatic cell line PT45 shows a mutation at codon 280 (AGA to AAA,
amino acid arginine to lysine) in conserved region V.
lung cancer (Chiba et al., 1990) and hepatocellular cancers
(Hsu et al., 1991; Bressac et al., 1991) there is a very high
frequency of G to T transversions, while in most other
tumour types there is an excess of G to A transitions (Baker
et al., 1989; Bartek et al., 1990; Nigro et al., 1990). These
differences have been interpreted as evidence of the involve-
ment of specific mutagenic agents in the various types. In
pancreatic cancer there is a strikingly high frequency of point
mutation at codon 12 of the Ki-ras oncogene. While there is
absolute restriction to this single codon of this single member
of the ras family, there is no particular base substitution. G
to A transitions and G to T transversions are identified in
about the same number of cases and G to C transversions
rather less commonly (Bos et al., 1989). Therefore we have
little evidence to indicate the action of a single mutagen in
the genesis of pancreatic cancer and this is consistent with
the relative lack of epidemiological evidence implicating
environmental agents in pancreatic carcinogenesis. Only a
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relatively weak association with environmental factors such
as cigarette smoking, alcohol and coffee drinking have been
described (Doll & Peto, 1976; McMahon, 1982). In contrast,
both hepatocellular cancer and non-small cell lung cancer
have relatively strong associations with potent environmental
carcinogens: hepatocellular cancer with hepatitis B virus and
aflatoxins, and lung cancer with cigarette smoking.
The molecular basis of pancreatic cancer is now becoming
clearer, and a number of independent genetic events have
been identified in human tumours (Lemoine & Hall, 1990). In
addition to a very high frequency of Ki-ras activation by
point mutation (Shibata et al., 1990), there is evidence of a
autocrine loop involving overexpression of transforming
growth factor alpha and the epidermal growth factor recep-
tor (Barton et al., 1991; Lemoine et al., 1991a). These abnor-
malities may be linked for there is in vitro evidence that
activation of ras oncogenes causes upregulation of TGF
alpha expression (Ciardello et al., 1990). Overexpression
(sometimes with amplification) of the c-erbB-2 proto-
oncogene has been described in about 20% of pancreatic
cancers (Hall et al., 1990). Now we have demonstrated in-
activation of the p53 tumour suppressor gene in a large
proportion of cases.
The relative importance and sequence of these genetic
events in pancreatic carcinogenesis remains to be determined,
although we do know that both overexpression of mutant
p53 and point mutation of Ki-ras are found in intraductal
carcinoma in situ lesions (this study and Lemoine et al.,
1991b). In vitro, normal human epithelial cells may be par-
tially transformed by activated ras oncogenes alone, but for
full malignant transformation an additional genetic event,
associated with immortalisation, is necessary (Bums et al.,
1991). This additional genetic event may involve the loss or
inactivation of a tumour suppressor gene. In patients with
Li-Fraumeni syndrome, characterised by a hereditary predis-
position to various tumours including pancreatic cancer,
germ-line mutations of the p53 gene have been described
(Malkin et al., 1990; Srivastava et al., 1990). In these
patients, p53 abnormalities are clearly the earliest genetic
event in tumorigenesis. In sporadic colorectal cancer, how-
ever, p53 mutation appears to be a late event and it has been
suggested that the order of events is not important, the net
result being dependent on the accumulation ofgenetic abnor-
malities (Baker et al., 1990; Vogelstein, 1991). In the pan-
creas carcinoma in situ and other lesions interpreted as
intermediate in the progression to invasive cancer are very
rarely reported by pathologists, and so it may be difficult to
pinpoint the appearance of p53 in the temporal sequence of
this tumour.
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